Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFIT: Immunotherapy Approaches Adapted for Fitness in Newly Diagnosed Transplant Ineligible Patients With Myeloma
NCT07649525Phase 3Recruiting
- Sponsor
- University of Leeds
- Start
- Jul 2026
- Primary completion
- Jun 2033
- Countries
- 1
01
Overview
A Phase 3 trial of teclistamab, talquetamab in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by University of Leeds. Started Jul 2026; status: recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT07649525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649525.